Inside Biogen's scramble to sell Aduhelm: Project 'Javelin' and pressure to ID as many patients as possible
In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a program called “Javelin,” a senior Biogen employee told Endpoints News.
The program identified about 800 centers for use, he said, and Biogen now pays for the use of bioassays to identify beta amyloid in potential patients having undergone a lumbar puncture procedure, the employee said — and one center preparing to administer the drug confirmed its participation in the bioassay program.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.